Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) on January 15, 2021. The filing discloses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and Secretary and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and the terms of a new employment agreement.
Material Changes
- Resignation: Brian McLaughlin notified the Board on January 15, 2021, of his retirement as Chief Financial Officer and Secretary, effective January 18, 2021.
- Appointment: John Morberg was appointed as the new Chief Financial Officer and Secretary, effective January 18, 2021.
- Compensation Structure: Mr. Morberg's employment agreement establishes an annual base salary of $410,000 and a target cash bonus of 55% of the base salary.
- Equity Grants: Mr. Morberg received a stock option for 100,000 shares (vesting over 3 years) and a restricted stock unit award for 17,500 shares (vesting in full on January 18, 2024).
Outlook, Risks, and Contingencies
The filing outlines specific severance provisions in the event of termination without "cause" or for "good reason," including 12 months of salary, pro-rated bonus, COBRA subsidies, and partial accelerated vesting of equity. In the event of a "change in control" within two years of termination, full accelerated vesting of equity awards applies. The filing notes no family relationships or undisclosed related party transactions involving Mr. Morberg.
Investor Verification Checklist
- Verify the transition timeline between the outgoing CFO (McLaughlin) and incoming CFO (Morberg) to ensure continuity of financial reporting.
- Review the attached Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason" regarding severance.
- Assess the impact of the new equity grants (100,000 options and 17,500 RSUs) on potential shareholder dilution.
- Confirm the press release (Exhibit 99.1) for any additional context on the leadership change not detailed in the 8-K.